WITHDRAWN: Correlations of CTLA-4 exon-1 rs231775A>G and promoter region rs5742909C>T polymorphisms with the therapeutic efficacy of 131 I radionuclide in Graves' disease

This study aimed to investigate the correlation of CTLA-4 exon-1 rs231775A>G and promoter region rs5742909C>T polymorphisms with the therapeutic efficacy of radionuclide 131 I in Graves9 disease amongst the Chinese Han population. The 131 I radionuclide therapy was applied to 261 patients with Graves9 disease. Based on therapeutic efficacy, the patients were assigned into the remission and the non-remission groups. PCR-RFLP was applied to detect CTLA-4 exon-1 rs231775A>G and promoter region rs5742909C>T polymorphisms. Haplotype analysis was conducted by means of SHEsis. The relation between various factors and 131 I therapy was detected by Logistic regression analysis. A close relationship was found between CTLA-4 rs231775A>G and the efficacy of 131 I treatment for Graves9 disease (AG + GG vs. AA: OR = 5.190, 95%CI = 1.390~19.430; G vs. A: OR = 2.204, 95%CI = 1.267~3.835). There was statistical significance in relation to the distribution of AC, GT and GC on Graves9 disease in the remission and non-remission groups (OR = 0.424, 95%CI = 0.227~0.791; OR = 1.976, 95%CI = 0.998~3.912; OR = 4.495, 95%CI = 2.770~7.294). Logistic regression analysis indicated that the CTLA-4 exon-1 rs231775A>G polymorphism (OR = 15.861, 95%CI = 1.601~157.089) and GT haplotype (OR = 1.375, 95%CI = 0.592~3.196) to be related factors of efficacy of 131 I therapy in Graves9 disease. The obtained results indicated that the CTLA-4 exon-1 rs231775A>G polymorphism and the GT haplotype may be correlated to the therapeutic efficacy of the radionuclide 131 I for patients with Graves9 disease.